Medincell Sa Stock Current Valuation
| MDCLF Stock | USD 34.39 0.00 0.00% |
Valuation analysis of MedinCell SA helps investors to measure MedinCell's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that MedinCell's price fluctuation is out of control at this time. Calculation of the real value of MedinCell SA is based on 3 months time horizon. Increasing MedinCell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MedinCell pink sheet is determined by what a typical buyer is willing to pay for full or partial control of MedinCell SA. Since MedinCell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MedinCell Pink Sheet. However, MedinCell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 34.39 | Real 35.08 | Hype 34.39 | Naive 39.65 |
The real value of MedinCell Pink Sheet, also known as its intrinsic value, is the underlying worth of MedinCell SA Company, which is reflected in its stock price. It is based on MedinCell's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of MedinCell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of MedinCell SA helps investors to forecast how MedinCell pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MedinCell more accurately as focusing exclusively on MedinCell's fundamentals will not take into account other important factors: MedinCell 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MedinCell's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MedinCell.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in MedinCell on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding MedinCell SA or generate 0.0% return on investment in MedinCell over 90 days. MedinCell is related to or competes with BioInvent International, Avacta Group, Healios KK, PureTech Health, GenSight Biologics, Northwest Biotherapeutics, and Verano Holdings. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers an... More
MedinCell Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MedinCell's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MedinCell SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1222 | |||
| Maximum Drawdown | 392.69 |
MedinCell Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedinCell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MedinCell's standard deviation. In reality, there are many statistical measures that can use MedinCell historical prices to predict the future MedinCell's volatility.| Risk Adjusted Performance | 0.1024 | |||
| Jensen Alpha | 5.72 | |||
| Total Risk Alpha | 3.68 | |||
| Treynor Ratio | 0.9357 |
MedinCell February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1024 | |||
| Market Risk Adjusted Performance | 0.9457 | |||
| Mean Deviation | 11.72 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 48.34 | |||
| Variance | 2336.49 | |||
| Information Ratio | 0.1222 | |||
| Jensen Alpha | 5.72 | |||
| Total Risk Alpha | 3.68 | |||
| Treynor Ratio | 0.9357 | |||
| Maximum Drawdown | 392.69 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
MedinCell SA Backtested Returns
MedinCell is out of control given 3 months investment horizon. MedinCell SA has Sharpe Ratio of 0.13, which conveys that the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to break down and interpolate sixteen different technical indicators, which can help you to evaluate if expected returns of 6.54% are justified by taking the suggested risk. Use MedinCell SA Risk Adjusted Performance of 0.1024, standard deviation of 48.34, and Mean Deviation of 11.72 to evaluate company specific risk that cannot be diversified away. MedinCell holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 6.35, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MedinCell will likely underperform. Use MedinCell SA variance, as well as the relationship between the maximum drawdown and rate of daily change , to analyze future returns on MedinCell SA.
Auto-correlation | 0.00 |
No correlation between past and present
MedinCell SA has no correlation between past and present. Overlapping area represents the amount of predictability between MedinCell time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MedinCell SA price movement. The serial correlation of 0.0 indicates that just 0.0% of current MedinCell price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 166.96 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, MedinCell SA has a Current Valuation of 190.33 M. This is 98.67% lower than that of the Healthcare sector and 95.9% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.86% higher than that of the company.
MedinCell Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedinCell's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedinCell could also be used in its relative valuation, which is a method of valuing MedinCell by comparing valuation metrics of similar companies.MedinCell is currently under evaluation in current valuation category among its peers.
MedinCell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 244.65 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 9.0 | |||
| Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.